ABBV · Full Picture

AbbVie Inc. — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 61
    1 forward row(s); quote_verified
    AbbVie's planned acquisition of Apogee Therapeutics is valued at $10.9 billion.
  2. Outstanding Indebtedness · Debt, leverage & refinancingPriority 61
    1 forward row(s); quote_verified
    AbbVie reportedly is seeking to raise at least $8 billion in debt to finance its acquisition of Apogee Therapeutics.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 58
    +10.2% revenue (realized); quote_verified
    AbbVie reported revenue up 10.2% year-over-year in Q2 2026.
  4. Guidance / Outlook · Guidance & outlookPriority 39
    1 forward row(s); quote_verified
    Analysts noted ABBV stock dipped about 4% after the company cut its 2026 EPS outlook to reflect the Apogee deal.
  5. Quarterly Dividend Declaration · Buybacks & dividendsPriority 32
    1 forward row(s); quote_verified
    AbbVie declared a quarterly dividend of $1.73 per share.
  6. Regulatory Approval Milestones · Regulatory action & investigationsPriority 32
    1 forward row(s); quote_verified
    The U.S. Food and Drug Administration (FDA) has accepted for review Allergan Aesthetics' supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for temporary improvement in the appearance of marked to very marked masseter muscle prominence in adults (announcement dated Aug. 4, 2026).

Threads by pillar

Revenue & Demand Priority 58 · 1 thread

Capital & Balance Sheet Priority 63 · 2 threads

Strategy & Portfolio Priority 61 · 1 thread

Legal, Regulatory & Policy Priority 32 · 1 thread

Guidance & Outlook Priority 39 · 1 thread

Expected impact by metric

metricforward netforward grossrealized
revenue——+10.2%